Biopharmaceutical aggregation

Combining experimental & computational approaches to understand, predict & control properties of biological molecules. Our infrastructure & expertise in biophysical & structural methods allows us to study molecular mechanisms of the aggregation process.

The rise in the development and approval of biotherapeutics has led to a raft of new challenges requiring solutions. One of these is the aggregation that can occur during the production of biopharmaceuticals at the volumes required for drug development and therapeutic dosing.

Work being done by our academics

The strong interdisciplinary culture means that each of our academics engaged in research are applying their expertise in a wide range of areas. Find out more:

MedImmune

Scientists at the University of Leeds are collaborating with the biopharmaceuticals company MedImmune to address some of the problems caused by protein aggregation. The hope is that the work will help accelerate the development of effective pharmaceutical treatments.

Read more